作者
Robin L Carhart-Harris, Mark Bolstridge, Camilla MJ Day, James Rucker, Rosalind Watts, David E Erritzoe, Mendel Kaelen, Bruna Giribaldi, Michael Bloomfield, Steve Pilling, James A Rickard, Ben Forbes, Amanda Feilding, David Taylor, HV Curran, David J Nutt
发表日期
2018/2
期刊
Psychopharmacology
卷号
235
页码范围
399-408
出版商
Springer Berlin Heidelberg
简介
Rationale
Recent clinical trials are reporting marked improvements in mental health outcomes with psychedelic drug-assisted psychotherapy.
Objectives
Here, we report on safety and efficacy outcomes for up to 6 months in an open-label trial of psilocybin for treatment-resistant depression.
Methods
Twenty patients (six females) with (mostly) severe, unipolar, treatment-resistant major depression received two oral doses of psilocybin (10 and 25 mg, 7 days apart) in a supportive setting. Depressive symptoms were assessed from 1 week to 6 months post-treatment, with the self-rated QIDS-SR16 as the primary outcome measure.
Results
Treatment was generally well tolerated. Relative to baseline, marked reductions in depressive symptoms were observed for the first 5 weeks post …
学术搜索中的文章
RL Carhart-Harris, M Bolstridge, CMJ Day, J Rucker… - Psychopharmacology, 2018